Invivyd, Inc. — Director's Dealing 2021

Aug 6, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Adagio Therapeutics, Inc. (ADGI)
CIK: 0001832038
Period of Report: 2021-08-05

Reporting Person: Adimab, LLC (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1985295	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$		Common Stock (25000000)		Direct
Series B Preferred Stock	$		Common Stock (220380)		Direct
Series C Preferred Stock	$		Common Stock (640320)		Direct

Footnotes

F1: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock is convertible at any time at the option of the
holder, without payment of additional consideration, into 5 shares of Common Stock, has no expiration date and is expected to automatically
convert into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.